Global Tigit Inhibitor Drug Opportunity And Clinical Research Insight 2022
December 22, 2021 ⚊ 1 Min read ⚊ Views 226 ⚊ HEALTH
T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is one of the most recently identified immune checkpoint inhibitor which is being evaluated as potential immunotherapeutic target. TIGIT is transmembrane glycoprotein receptor with Ig-like V-type domain and an ITIM in its cytoplasmic domain and is expressed on wide range of cells including memory T-cells, NK cells, and Tregs. Apart from this, studies have demonstrated high expression of TIGIT on wide range of solid tumors and hematological malignancies, thus making it potential target in drug development.
Tags: life sciences industry report, tigit inhibitor market research report
